Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/17/21 → 10/30/26 |
Funding
- Novartis (domestic): $475,990.00
Phase III, Multi-Center, Open-Label, Randomized Study Of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia In Chronic Phase
- Munker, Reinhold (PI)